Type 1 diabetes (T1D) is a T cell-dependent autoimmune disease that is characterized by the destruction of insulin-producing b cells in the pancreas. The administration to patients of ex vivo-differentiated FoxP3 + regulatory T (T reg ) cells or tolerogenic dendritic cells (DCs) that promote T reg cell differentiation is considered a potential therapy for T1D; however, cell-based therapies cannot be easily translated into clinical practice. We engineered nanoparticles (NPs) to deliver both a tolerogenic molecule, the aryl hydrocarbon receptor (AhR) ligand 2-(1′H-indole-3′-carbonyl)-thiazole-4-carboxylic acid methyl ester (ITE), and the b cell antigen proinsulin (NP ITE+Ins ) to induce a tolerogenic phenotype in DCs and promote T reg cell generation in vivo. NP ITE+Ins administration to 8-week-old nonobese diabetic mice suppressed autoimmune diabetes. NP ITE+Ins induced a tolerogenic phenotype in DCs, which was characterized by a decreased ability to activate inflammatory effector T cells and was concomitant with the increased differentiation of FoxP3 + T reg cells. The induction of a tolerogenic phenotype in DCs by NPs was mediated by the AhR-dependent induction of Socs2, which resulted in inhibition of nuclear factor kB activation and proinflammatory cytokine production (properties of tolerogenic DCs). Together, these data suggest that NPs constitute a potential tool to reestablish tolerance in T1D and potentially other autoimmune disorders.
INTRODUCTION
Type 1 diabetes (T1D) is a T cell-mediated autoimmune disease characterized by the destruction of insulin-producing b cells in the pancreas (1, 2) . Therefore, the reestablishment of immune tolerance is a major goal for the treatment of T1D. Immunologic tolerance is mediated by a number of mechanisms including the removal and inactivation of self-reactive pathogenic T cell clones, as well as their active regulation by specialized regulatory cells. Several regulatory T (T reg ) cell subsets mediate immune tolerance. One such subset of particular importance is the FoxP3 + T reg cell population (3, 4) . Deficits in pancreatic T reg cells in both number and functionality have been described in recent-onset T1D patients (5, 6) . Conversely, therapies that increase T reg cell numbers or functions prevent and treat T1D in preclinical models and are currently under investigation in clinical trials (7) (8) (9) .
The administration of ex vivo-expanded (increased in number) T reg cells or tolerogenic dendritic cells (DCs) that promote the proliferation of T reg cells in vivo is a potential therapeutic approach for T1D, but cell-based therapeutic approaches are hard to translate into clinical practice (10, 11) . Alternatively, antibody-and cytokine-based therapies have been developed to restore immune tolerance and suppress autoimmunity in T1D (12, 13) . However, these approaches can lead to generalized immune suppression. Thus, there is an unmet clinical need for therapeutic approaches to generate functional antigen-specific T reg cells in vivo as a method for the reestablishment of immune tolerance in T1D and other autoimmune disorders.
To generate tolerogenic DCs and promote T reg cell generation in vivo, we used nanoparticles (NPs) to co-deliver a tolerogenic molecule, the aryl hydrocarbon receptor (AhR) ligand 2-(1′H-indole-3′-carbonyl)-thiazole-4-carboxylic acid methyl ester (ITE), and the b cell antigen proinsulin (NP ITE+Ins ). We found that NP ITE+Ins administration to 8-week-old nonobese diabetic (NOD) mice suppressed the spontaneous development of T1D. NP ITE+Ins induced a tolerogenic phenotype in DCs characterized by decreased activation of inflammatory effector T cells and was concomitant with the increased differentiation of FoxP3 + T reg cells. Tolerogenic DC induction by these particles was dependent on the AhR-dependent induction of Socs2, which interfered with nuclear factor kB (NF-kB) activation and the production of proinflammatory cytokines. Collectively, these data suggest that NPs constitute a potential tool to reestablish tolerance in T1D and other autoimmune disorders.
RESULTS

Generation of NPs containing b cell antigens and the tolerogenic AhR ligand ITE
We (14, 15) and others (16) (17) (18) (19) (20) showed that AhR activation induces a tolerogenic phenotype in DCs, which promotes the differentiation of naïve CD4 + T cells into T reg cells. Insulin harbors epitopes that are targeted by diabetogenic and regulatory CD4 + and CD8 + T cells (7, 21, 22) , and insulin has been identified as an initiating autoantigen in T1D (23) . On the basis of these results and the need for methods to reestablish immune tolerance in T1D, we constructed NPs containing the tolerogenic AhR ligand ITE and a b cell-related recombinant antigen, such as proinsulin (NP ITE+Ins ) (Fig. 1A) or a mimotope peptide (MIMO) that activates the diabetogenic CD4 + T cell clone BDC2.5 (NP ITE+MIMO ) (24) . As a substrate, we used gold NPs because they show minimal toxic or immunogenic activity in humans (25, 26) . Unloaded NPs (NP), NPs loaded with ITE alone (NP ITE ), or NPs loaded with antigen alone [for example, proinsulin (NP Ins )] were used as controls. NP solubility and stability were improved by adding a layer of thiol-polyethylene glycol (PEG). Transmission electron microscopy (TEM) studies showed that the different groups of NPs presented a round morphology and monodispersed distribution of particle diameter of about 60 nm (Fig. 1B) . The loading of NPs with ITE did not decrease the amount of antigen that could be loaded onto the NPs (Fig. 1C) . Conversely, all ITE-containing NPs (NP ITE and NP ITE+Ins ) showed comparable AhR agonistic activity, suggesting that antigens in the NPs did not interfere with the loading of ITE or its ability to activate AhR (Fig. 1D) .
Administration of NP ITE+Ins arrests spontaneous T1D in NOD mice
On the basis of the tolerogenic effects of the AhR ligand ITE (14), we studied the effects of NPs on autoimmune T1D in NOD mice. We first used the cyclophosphamide-accelerated model of diabetes (CAD) (27, 28) to study the effects of NPs on T1D development. NPs were administered weekly (6 mg per mouse) starting 1 week before CAD induction in 8-weekold naïve NOD mice as described previously (27, 28) . NP ITE+Ins suppressed the development of T1D 4 weeks after CAD induction ( fig.  S1 ), whereas NP Ins had no effect on CAD development, and NP Ins stimulated a trend toward amelioration of T1D symptoms that was not statistically significant ( fig. S1 ). Hence, in follow-up studies, we focused on the effects of NP ITE+Ins on spontaneous T1D in NOD mice. Naïve 8-week-old female NOD mice were treated weekly with NPs, and the spontaneous development of T1D was monitored. We found that NP ITE+Ins administration arrested T1D development as determined by measurement of blood glucose concentrations and the histological analysis of pancreatic samples (Fig. 2, A to C) . b Cell-specific effector T cells drive T1D immune pathogenesis (1, 2, 29) . Consistent with the arrest of T1D development, we detected decreased expression of the genes Tbx21 and Rorc [which encode the transcription factors Tbet and RoRgt, which are required for the generation of the proinflammatory T helper 1 (T H 1) and T H 17 subsets, respectively] in T cells isolated from the pancreatic lymph nodes of NP ITE+Ins -treated mice (Fig. 2D) . Conversely, Foxp3 expression, which is required for T reg cell generation, was increased under these conditions (Fig. 2D) .
To further investigate the effects of NPs on the b cell-specific T cell response in vivo, we used BDC2.5 T cell receptor (TCR) transgenic NOD mice (24) . The BDC2.5 TCR was isolated from NOD diabetogenic CD4 + T cell clones that target b cell antigens expressed in both NOD mice and humans (30) (31) (32) . We found that NP ITE+MIMO administration to BDC2.5 transgenic NOD mice decreased the percentage of interferon-g-producing (IFN-g + ) and interleukin-17-producing (IL-17
+ T cells in pancreatic lymph nodes (Fig. 2E ). This decrease was concomitant with an increase in Foxp3 expression and in the percentage of FoxP3 + T reg cells in the pancreas (Fig. 2, F and G) . Together, these data suggest that NPs loaded with ITE and a b cell-related antigen limit the diabetogenic T cell response. We then investigated the effects of NP ITE+MIMO on DCs in vivo. Treatment with NP ITE+MIMO did not affect the recruitment to the pancreas of classic DCs linked to T cell activation (Fig. 2H) . However, NP ITE+MIMO administration enhanced the expression of the AhR-responsive gene Cyp1a1 in DCs (Fig. 2I) . Moreover, after activation with the Toll-like receptor 4 (TLR4) agonist lipopolysaccharide (LPS) ex vivo, DCs isolated from NP ITE+MIMO -treated mice showed decreased expression of Il6 and Il12a (Fig. 2J) , which encode the cytokines IL-6 and IL-12, suggesting that NP ITE+MIMO administration induced tolerogenic DCs in vivo.
To study the relevance of these tolerogenic DCs for the arrest of T1D by NP ITE+Ins administration, we performed transfer experiments with NPloaded DCs. Bone marrow-derived DCs (BMDCs) were incubated for 24 hours with NPs, washed, and injected intravenously into 6-week-old naïve NOD mice. This treatment was repeated three additional times, once every 4 days, and the development of spontaneous T1D was monitored. We found that treatment with NP ITE+Ins -loaded DCs reduced the development of spontaneous T1D in NOD mice, such that 40% of the NOD recipients treated with BMDCs loaded with empty NP developed diabetes by the age of 22 weeks as compared to 10% of the mice that received DCs that had been loaded with NP ITE+Ins ( fig. S2 ; P < 0.001). Together, these data suggest that NP ITE+Ins administration induces tolerogenic DCs that suppress spontaneous T1D development in NOD mice.
AhR-targeting NPs induce tolerogenic DCs
On the basis of our findings on the effects of AhR-targeting NPs on T1D development and DC activation in NOD mice, we studied the effects of NPs on DCs from NOD mice in vitro. We found that NPs were taken up by splenic DCs within 1 hour of incubation (Fig. 3A) . Accordingly, the expression of Cyp1a1, which is transcriptionally controlled by AhR, was increased by ITE-containing NPs (NP ITE and NP ITE+MIMO ) but not by NP alone or NP MIMO (Fig. 3B) . Similar results were observed with BMDCs ( fig. S3) .
DCs control the activation and differentiation of T cells through the expression of costimulatory molecules and the production of polarizing cytokines (33) (34) (35) (36) . Thus, we studied the effects of NPs on the activation of splenic DCs incubated in vitro with Escherichia coli LPS. Administration of NP ITE or NP ITE+MIMO to LPS-treated DCs decreased the cell surface abundances of the class II major histocompatibility complex (MHC II) and the costimulatory molecules CD40 and CD80, whereas they increased the cell surface abundance of CD86 (Fig. 3C) . NP ITE and NP ITE+MIMO administration to LPS-treated DCs also decreased the expression One week after the last NP administration, the percentages of DCs within pancreatic lymph nodes were analyzed by flow cytometry. cDC, classical dendritic cell. (I) DCs isolated from the NP-treated mice described in (H) were subjected to qPCR analysis of the abundance of Cyp1a1 mRNA normalized to that of Gapdh mRNA. (J) DCs isolated from the indicated NP-treated mice were treated with LPS for 24 hours and then were subjected to qPCR analysis of the abundances of Il6 and Il12a mRNAs normalized to that of Gapdh mRNA. Data are means ± SEM from one representative experiment of at least three independent experiments. All experiments were performed with at least three biological samples. *P < 0.05, **P < 0.01, and ***P < 0.001. Each experiment was performed with at least three biological samples. *P < 0.05, **P < 0.01, and ***P < 0.001.
of Il12a and Il6, which encode the cytokines IL-12 and IL-6 that promote the differentiation of naïve CD4 + T cells into T H 1 and T H 17 cells, respectively (Fig. 3D) . Conversely, NP ITE+MIMO administration increased the expression of Il10, which encodes the anti-inflammatory cytokine IL-10, but did not alter the expression of Ido1, which has been linked to the antiinflammatory effects of AhR in other experimental systems (Fig. 3E ) (17, 37, 38) .
To study how the NP-induced modulation of DCs affected T cell responses, we treated splenic DCs from NOD mice with NPs and then used these cells to activate naïve CD4 + T cells from BDC2.5 mice. We found that NP MIMO -treated DCs induced the proliferation of BDC2.5 T cells (Fig. 3F) , as well as the generation of IFN-g and IL-17 mRNA and protein by these cells without the need to add exogenous MIMO (Fig. 3, G to I) , which suggests that MIMO in the NPs was delivered to the DCs and then presented to the T cells. Consistent with a tolerogenic role for AhR signaling in DCs, NP ITE+MIMO -treated DCs were less potent at inducing the proliferation of BDC2.5 T cells and their production of IFN-g and IL-17 ( Fig. 3, F to I) . Concomitantly, the generation of FoxP3 + CD4 + T cells was increased under conditions in which BDC2.5 T cells were incubated with NP ITE+MIMO -treated DCs (Fig. 3I) , which increased the ratio of FoxP3 + to IL-17 + T cells and the ratio of FoxP3 + to IFN-g + T cells (Fig. 3J) . Together, these results suggest that AhR-targeting NPs induce a tolerogenic phenotype in DCs.
AhR activation with NPs inhibits NF-kB signaling in DCs
To investigate the mechanisms involved in the tolerogenic effects of NP ITE+Ins , we used NanoString nCounter arrays to analyze the transcriptional programs of splenic DCs isolated from NP-treated NOD mice and of DCs treated in vitro with NPs. When compared with empty NPs and NP Ins , NP ITE+Ins decreased the expression of genes whose products are associated with DC activation and maturation, as well as the production of proinflammatory mediators and molecules linked to T1D pathogenesis (Fig. 4A) . Among these pathways, we detected statistically significant effects of NP ITE+Ins on signaling by p38 mitogen-activated protein kinase (MAPK), extracellular signal-regulated kinase 1 (ERK1) and ERK2, and NF-kB, all of which play an important role in the regulation of inflammation (Fig. 4, A and B) . To validate these findings, we analyzed the effects of NPs on these pathways using Western blotting. We found that NP ITE+Ins administration resulted in reduced activation and translocation of the p65 subunit to the nucleus in splenic DCs (Fig. 4C) . No statistically significant effects on p38 MAPK activation by the NPs were detected, but we observed a trend toward inhibition of ERK1/2 activation by NP ITE+Ins administration (Fig. 4C) .
The AhR ligand 2,3,7,8-tetrachlorodibenzodioxin (TCDD) induces Socs2 expression in B cells (39) . Moreover, SOCS2 interferes with NF-kB activation by suppressing the activation of tumor necrosis factor (TNF) receptor-activating factor 6 (TRAF6) (40) . Thus, we analyzed the effects of NPs on Socs2 expression in DCs. Consistent with our transcriptional analysis, we detected a statistically significant increase in the expression of Socs2, but not Socs1 or Socs3, in DCs treated in vitro with NP ITE+Ins (Fig. 4D and fig. S4A ). Concomitantly, when compared to NP administration, NP ITE+Ins administration reduced the abundance of TRAF6 in LPS-activated DCs (Fig. 4E) . A bioinformatics analysis of the Socs2 promoter identified three potential AhR-binding sites (xenobiotic responsive elements; XRE-1, XRE-2, and XRE-3) (Fig. 4F) . Chromatin immunoprecipitation (ChIP) studies showed a substantial recruitment of AhR to the Socs2 locus in DCs treated with NP ITE+Ins (Fig. 4F) . To study the role of AhR in the induction of Socs2 expression by NP ITE+Ins administration, we used DCs carrying the AhR-d hypomorphic allele, which shows reduced sensitivity to AhR agonists (41) . We found that deficient AhR signaling in AhR-d DCs abrogated the induction of Socs2 expression by NP ITE+Ins administration (Fig. 4G) . Thus, AhR activation by NP ITE+Ins increases Socs2 expression in DCs.
To study the potential role for SOCS2 in mediating the effects of NP ITE+Ins on NF-kB activation and DC function, we knocked down Socs2 with small interfering RNAs (siRNAs). The silencing of Socs2 in DCs was specific and did not result in a statistically significant reduction in the expression of Socs1 or Socs3, which can also inhibit NF-kB activation (fig. S4B ). The knockdown of Socs2 abrogated the suppression of NF-kB p65 activation by NP ITE+Ins administration and reverted the effects of NP ITE+Ins on the expression of and Il12a and Il6 by DCs (Fig. 4, H and I) . Moreover, the knockdown of Socs2 abrogated the ability of NP ITE+Ins to suppress the generation of T H 1 and T H 17 cells induced by DCs (Fig. 4J) . Together, these data suggest that the tolerogenic effects of NP ITE+Ins involve the inhibition of NF-kB signaling in DCs through a SOCS2-dependent mechanism.
AhR activation with NPs induces human tolerogenic DCs
To evaluate the translational potential of NPs, we studied their effects on human monocyte-derived DCs (hDCs). For these studies, we used NPs carrying ITE and glutamic acid decarboxylase (GAD 555-567 ), a major target of autoimmune T cells in human T1D (NP ITE+GAD ) (1, 2, 29). As expected, NP ITE+GAD administration activated AhR in hDCs, increasing the expression of the AhR target gene Cyp1a1 (Fig. 5A) . Treatment with NP ITE+GAD also modulated the expression of genes involved in the activation and function of antigen-presenting cells (APCs), including genes whose products participate in NF-kB signaling (Fig. 5, B and C) . Treatment of hDCs with NP ITE+GAD decreased the cell surface abundances of the costimulatory molecules CD40 and CD86 (Fig. 5D ), which suggests that NP ITE+GAD administration induced a tolerogenic phenotype in hDCs. To investigate the functional relevance of these observations, we used NP-treated hDCs to activate the 325 GADreactive CD4 + T cell line, which was isolated from a T1D patient (42) . We found that treatment of mature or immature hDCs with NP ITE+GAD decreased their ability to stimulate IFN-g production by the T cells (Fig.  5E ). Together, these data suggest that NP ITE+GAD promote the generation of tolerogenic hDCs that have an impaired ability to stimulate the activation of human diabetogenic T cells.
DISCUSSION
The reestablishment of antigen-specific tolerance is a potential therapeutic approach for T1D. We found that the NP-based coadministration of a b cell antigen and the tolerogenic AhR ligand ITE suppressed the spontaneous development of T1D in NOD mice. These protective effects involved the control of the diabetogenic immune response by tolerogenic DCs and T reg cells. Given that treatment in our studies was initiated when mice were 8 to 10 weeks old, a time at which insulitis is already detectable (43), our results suggest that NPs provide a therapeutic avenue to reestablish antigen-specific tolerance in T1D and perhaps in other immune-mediated diseases.
Both T H 1 and T H 17 cells can induce diabetes in NOD recipient mice (44); however, the induction of diabetes by T H 17 cells is associated with the coexpression of IFN-g (44) . Tbet expression in T cells is required for T1D development in NOD mice (45) , and although loss of IL-17 ameliorates autoimmunity in the central nervous system, it fails to affect T1D development in NOD mice (46) . Together, these data suggest that T H 1 cells play a dominant role in the diabetogenic response in NOD mice. Furthermore, the arrest of diabetes with NP ITE+Ins was linked to a stronger reduction in the frequency of T H 1 cells than in the frequency of T H 17 cells.
Because NP ITE+Ins inhibited the production of both T H 1-and T H 17-polarizing cytokines by DCs in vitro, these observations likely reflect the increased susceptibility of T H 1 cells to inhibition in vivo, the differential targeting of specific T H 1-inducing APCs, or both. In addition, given that T1D in NOD mice is also driven by CD8 + T cells (2), our data suggest that NP ITE+Ins also control the CD8 + T cell response; however, additional studies are needed to investigate the specific effects of NP ITE+Ins on the diabetogenic CD8 + T cell response and the mechanisms involved. (52, 53) . Given reports that describe that effector T cells in T1D patients are resistant to regulation by certain T reg cells (7) (8) (9) , the induction of multiple T reg cell populations is likely to boost the therapeutic potential of NPs. Gold NPs similar to those used in our studies are reported to be taken up by T cells in the context of tumors (54) , suggesting that AhR activation in T cells by NPs may directly promote the differentiation of T reg cells (41, 55, 56) . However, the molecular and functional data presented in this study suggest that the tolerogenic effects of NPs are mediated, at least partially, by DCs.
Several pathways control the anti-inflammatory functions of DCs. For example, IL-27 signaling and the cell surface expression of CD39 in DCs limit T cell-mediated inflammation (34) . The tolerogenic effects of NPs used in our studies were mediated by an AhR-SOCS2 axis and are consistent with previous reports of the anti-inflammatory effects of AhR signaling in DCs (14, 15, 17, 19, 20) . SOCS protein production is induced in innate immune cells by the activation of pattern recognition receptors, which results in the control of inflammation. For example, SOCS1 and SOCS3 inhibit the activation of the Janus-activated kinase (JAK)-signal transducer and activator of transcription (STAT) pathway in DCs, limiting the production of proinflammatory cytokines (57, 58) . Moreover, SOCS1 inhibits the NF-kB signaling pathway by stimulating the ubiquitylation and degradation of the Toll-interleukin-1 receptor (TIR) domain-containing adaptor protein (TIRAP) in the cytoplasm, p65 in the nucleus, or both (59, 60) .
SOCS2 signaling in T cells is linked to the induction of Foxp3
+ T reg in response to treatment with anti-CD3 antibody (61) and the maturation of hDCs (62, 63) . Our work identifies SOCS2 as a mediator of the tolerogenic effects of AhR in DCs through the control of TRAF6 abundance and the inhibition of NF-kB activation. At this point, it is unclear whether the inhibitory effects of the AhR-SOCS2 axis are mediated solely by control of TRAF6 abundance, or whether they also involve the direct inhibition of p65. However, these data are consistent with the AhR-dependent decrease in TRAF6 abundance and the inhibition of NF-kB triggered by lipoxin A 4 in DCs (40, 64) . Thus, together with the production of retinoic acid and kynurenine that have been previously linked to AhR (14, 17, 37, 38) , increasing the abundance of SOCS2 is a mechanism by which AhR controls DC activation. Future studies should determine whether these or other AhR-dependent immunomodulatory mechanisms are associated with specific APC types.
Several strategies have been pursued to modulate antigen-specific responses in vivo. Tolerogenic antigen administration arrests antigen-specific T cell responses, but its success in the arrest of T1D has been limited (65) . DNA vaccines showed promising results in experimental models of autoimmunity and human clinical trials (27, 66) . More recently, it was reported that NP-administered antigens induce tolerance (15, 51, 67) . The strategy that we described here enhances the induction of tolerance by coadministering autoantigens and the tolerogenic AhR ligand ITE with NPs. In combination with methods for the identification of the specific autoantigens targeted in each T1D patient (28, 68) , NPs offer a new therapeutic avenue for the treatment of T1D and potentially of other autoimmune diseases (15) .
MATERIALS AND METHODS
Mice and reagents
NOD and BDC2.5 mice (24) were purchased from The Jackson Laboratory and kept in a pathogen-free facility at the Harvard Institutes of Medicine. All experiments were performed in accordance with the guidelines of the standing committee of animals at Harvard Medical School. In all of the studies described here, the mice were randomly assigned to each of the experimental groups. Blood glucose was measured weekly, and mice with blood glucose concentrations of ≥200 mg/dl were deemed diabetic. For the induction of CAD, 4 mg of cyclophosphamide monohydrate (Sigma-Aldrich) was injected intraperitoneally into mice twice, 7 days apart.
Human T cell clone
The 325GAD T cell clone was generated by H. Reijonen (Benaroya Research Institute at Virginia Mason University, Seattle, WA) from the peripheral blood of a T1D patient by sorting and inducing the proliferation of CD4 + T cells that bound to a human leukocyte antigen (HLA)-DRB1*04:04 tetramer loaded with hGAD65 555-567(557F→I) (42) . The substituted peptide stabilizes binding to the tetramer, and the T cell clone recognizes the native peptide (NFFRMVISNPAAT) and the substituted peptide in the context of HLA-DRB1*04:01 and DRB1*04:04. The native peptide was used in all of the experiments described here.
NP preparation
NPs were produced with ultrapure water, 60-nm tannic, acid-stabilized gold particles at a concentration of 2.6 × 10 10 particles/ml (Ted Pella Inc.), methoxypolyethylene glycol (mPEG)-SH (with a molecular mass of 5000 kD; Nektar Therapeutics), ITE (Tocris Bioscience), MIMO peptide (MEVGWYRSPFSRVVHLYRNGK, cat. #62756; AnaSpec Inc.), and proinsulin. Freshly prepared solutions of 3.5 mM ITE, protein, or peptide (1 mg/ml) were added dropwise to a rapidly mixing gold colloid at a 1:6 ITE solution/colloid volume ratio, which facilitated even distributions of the molecules on the gold particle surface (69) . After a 30-min incubation at room temperature, 10 mM mPEG-SH was added dropwise to the colloids, with a minimum ratio of 30,000 PEG-SH molecules per 60-nm gold particle. The resulting PEG monolayer stabilized gold colloids against aggregation under various conditions (69) . Note that the addition of a 10-to 20-fold excess of PEG-SH does not affect colloid stability or the thickness of the polymer-coating layer (69) . After an additional 30-min incubation at room temperature, the colloids were pelleted by centrifugation, resuspended in ultrapure water, and characterized by ultraviolet-visible spectroscopy and TEM. The incorporation of peptide or protein onto the NPs was assessed with the fluorescence-based LavaPep Peptide Quantification Kit (FLUOROtechnics).
Flow cytometric analysis
To detect intracellular cytokines, cells were stimulated in culture medium containing phorbol 12-myristate 13-acetate (50 ng/ml; Sigma-Aldrich), ionomycin (1 mg/ml; Calbiochem), and GolgiStop (BD Biosciences) for 4 hours. After the staining of cell surface markers, cells were fixed, permeabilized, and incubated with cytokine-specific antibodies (at a 1:100 dilution) at 25°C for 30 min before the cells were analyzed by flow cytometry according to standard protocols.
DC isolation and generation
Murine DCs were purified from the spleens of naïve NOD mice with CD11c + magnetic beads (Miltenyi) according to the manufacturer's instructions. Cells were incubated with NP and used to stimulate BDC2.5 + CD4 + T cells. To generate BMDCs, bone marrow cells were isolated from the femurs of naïve NOD mice and cultured for 7 days in the presence of granulocyte-macrophage colony-stimulating factor (GM-CSF; 20 ng/ml) and IL-4 (10 ng/ml). On day 7, the cells were purified with CD11c + magnetic beads. To generate hDCs, venous blood was drawn from HLA-typed DR4 + individuals from the University of Massachusetts Adult Diabetes Clinic with Internal Review Board approval. The tissue types for the healthy control subjects and the T1D patient were as follows: healthy control 1, 70-year-old female (A26, A31, DRB1*04:01, DRB1*01:01, DQ3, DQ5); healthy control 2, 49-year-old female (A1, A11, DR4, DR15); healthy control 3, 57-year-old female (A1, A24, DRB1*04:07, DRB1*13:02); and T1D patient, 58-year-old female with T1D for 50 years (A2, A33, DRB1*04:04, DRB1*01:02, DQ3, DQ5). Heparinized blood was centrifuged in the presence of Ficoll, and peripheral blood mononuclear cells were recovered and plated at 5 × 10 6 cells/ml in HL-1 medium supplemented with 2 mM L-glutamine, 5 mM Hepes, penicillin (100 U/ml), streptomycin (100 mg/ml), 0.1 mM each of nonessential amino acids, 1 mM sodium pyruvate (all from Lonza), and 5% heat-inactivated human male AB serum (Omega Scientific) for 3 hours, and then nonadherent cells were removed. Recombinant human IL-4 (rhIL-4; 5 ng/ml) and rhGM-CSF (100 ng/ml) were then added to the culture medium. Five days later, cells were harvested; were either used as immature DCs or matured overnight in culture with rhTNF-a (50 ng/ml), rhIL-1b (10 ng/ml), and LPS (100 ng/ml) (cytokines from R&D Systems; LPS from Sigma-Aldrich); and were used as mature DCs.
Mouse T cell differentiation in vitro BDC2.5 + CD4 + T cells were activated by coculture with BMDCs or splenic DCs at a 3:1 (100,000:30,000) T cell to DC ratio and MIMO (20 mg/ml) as described previously (11) . 
Real-time qPCR assays
RNA was extracted from DCs and T cells with the RNeasy Mini Kit (Qiagen); complementary DNA was prepared; and qPCR assays were performed with an ABI 7500 cycler (Applied Biosystems).The abundances of mRNAs of interest were expressed relative to the abundance of Gapdh mRNA.
Transmission electron microscopy
NPs that had been incubated with DCs were fixed in the dish for at least 1 hour at room temperature with 2.5% (v/v) glutaraldehyde, 1.25% (v/v) paraformaldehyde (PFA), and 0.03% picric acid in 0.1 M sodium cacodylate buffer (pH 7.4). The cells were then postfixed for 30 min in 1% OsO 4 / 1.5% (w/v) KFeCN 6 , washed in water three times, and incubated in 1% aqueous uranyl acetate for 30 min, which was followed by two washes in water and subsequent dehydration in grades of alcohol [5 min each: 50, 70, and 95% (v/v) and twice at 100%]. Cells were removed from the dish in propylene oxide, pelleted at 1000g for 3 min, and infiltrated for 2 hours in a 1:1 mixture of propylene oxide and TAAB Epon (Marivac). The samples were then embedded in TAAB Epon and polymerized at 60°C for 48 hours. Ultrathin sections (about 60 nm in thickness) were cut on a Reichert Ultracut-S microtome, picked up onto copper grids stained with lead citrate, and examined in Tecnai G2 Spirit BioTWIN. Images were recorded with an Advanced Microscopy Techniques 2k CCD camera.
Histology
Pancreata were fixed in 4% PFA, cut, and stained by standard hematoxylin and eosin, and the average degree of insulitis was assessed over 20 islets scored per pancreas by an investigator blinded to treatment. Each islet was classified as "clear" if no infiltrate was detected, "mildly infiltrated" if periinsulitis or an intra-islet infiltrate occupied less than 25% of the islet, or "infiltrated" or "heavily infiltrated" if 25 to 50% or >50%, respectively, of the islet was occupied by inflammatory cells.
BMDC transfer experiments
BMDCs were generated as described earlier. On day 7, NPs were added to the cells, and 24 hours later, the cells were purified with CD11c + magnetic beads. DCs (1 × 10 6 to 2 × 10 6 cells per mouse) were then extensively washed and transferred intravenously into 8-week-old female NOD recipient mice four times, once every 4 days. Blood glucose concentrations were measured weekly. Mice with glycemia >200 mg/dl were considered to be diabetic.
ChIP assays
Cells were cross-linked with 1% PFA and lysed with the appropriate lysis buffer [1% SDS, 10 mM EDTA, 50 mM tris-HCl (pH 8.1)] containing 1× protease inhibitor cocktail (Roche Molecular Biochemicals). Chromatin was sheared by sonication, and supernatants were collected after centrifugation and diluted in buffer [1% Triton X-100, 2 mM EDTA, 150 mM NaCl, 20 mM tris-HCl (pH 8.1)]. Five milligrams of antibody was prebound for a minimum of 4 hours to protein A/G Dynal magnetic beads (Invitrogen), washed three times with ice-cold phosphate-buffered saline containing 5% bovine serum albumin, and then added to the diluted chromatin before being immunoprecipitated overnight. The magnetic bead-chromatin complexes were washed three times with radioimmunoprecipitation assay buffer [50 mM Hepes (pH 7.6), 1 mM EDTA, 0.7% sodium deoxycholate, 1% NP-40, 0.5 M LiCl] and then twice with tris-EDTA buffer. Immunoprecipitated chromatin was extracted with 1% SDS, 0.1 M NaH-CO 3 and then heated at 65°C for at least 6 hours to reverse the PFAinduced cross-linking. DNA fragments were purified with a QIAquick DNA Purification Kit (Qiagen) and analyzed by SYBR Green real-time PCR (Takara Bio Inc.). Anti-SOCS2 antibody (cat. #2779; Cell Signaling Technology) was used for ChIP. The following primer pairs were used: AhR (XRE-1), 5′-GGAATGGAGCGGACAGGA-3′; (forward) and 5′-GGA-ATGGAGCGGACAGGA-3′ (reverse); AhR (XRE-2), 5′-ATGAGTCAA-CACGTCCCAGA-3′ (forward) and 5′-CTGCACACTCTCGTTTTGGG-3′ (reverse); and AhR (XRE-3), 5′-TGGCAAAGTCTCTCGCAGA-3′ (forward) and AhR (XRE-3) reverse, 5′-TGCTCGGGGTTAAATGG-TAC-3′ (reverse).
Western blotting analysis
DCs were lysed with the appropriate amount of lysis buffer (Cell Fractionation Kit, cat. #9038; Cell Signaling Technology), and cytoplasmic and nuclear fractions were saved for protein quantification (cat. #23235; Thermo Scientific). Lysates of DCs were resolved by electrophoresis through 4 to 12% bis-tris NuPAGE gels (Invitrogen) and were transferred onto polyvinylidene difluoride membranes (Millipore). The membranes were then 
siRNA-mediated knockdown
BMDCs were transfected with SMARTpool: ON-TARGETplus Socs2 siRNA (cat. #L-044410-01-0005; Dharmacon) with the GeneSilencer siRNA Transfection Reagent (cat. #T5000; Genlantis) according to the manufacturer's protocol. A nonspecific siRNA was used as a negative control.
Statistical analysis
GraphPad Prism software was used for statistical analysis. For comparison of two groups, linear regression with 95% confidence interval and unpaired two-tailed Student's t test were used. A one-way analysis of variance (ANOVA) test for paired data was used to determine the statistical significance of the time-response curves. Values of P < 0.05 were considered to be statistically significant.
SUPPLEMENTARY MATERIALS
www.sciencesignaling.org/cgi/content/full/9/433/ra61/DC1 Fig. S1 . NP ITE+Ins administration suppresses CAD in NOD mice. 
